Pharmaceutical Development of Biosimilars: Challenges and Prospects

Keywords

Biosimilars
biologics
immunogenicity
regulatory pathways
analytical characterization
bioprocessing
pharmacovigilance

Abstract

Biosimilars, as highly similar alternatives to originator biologic drugs, are poised to transform the pharmaceutical landscape by offering cost-effective therapeutic options. However, their development is complex, involving stringent regulatory pathways, analytical characterization, and clinical validation. This article explores the multifaceted challenges in biosimilar development, such as structural heterogeneity, immunogenicity concerns, and manufacturing scalability. It also highlights the evolving global regulatory frameworks and future trends that promise a more streamlined approach to biosimilar approval. With advancements in analytical technologies and bioprocessing, biosimilars have the potential to enhance patient access to life-saving biologics without compromising quality or efficacy.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2021 Dr. Hira Naveed (Author)